Today: 8 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 23 November 2025 - 9 December 2025

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2 Over the past six months, GPCR has already delivered a multi‑bagger move, with one analyst note calculating a ~241% gain even before today’s opening bell. The stock now sits near its 52‑week high, with a 52‑week range of about $13.22 to $94.90 and a market
9 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about $18.52 per share, pushing the company’s market cap to around $3.0 billion as of early December 9. MLQ At the same time, Wave launched a $250 million public equity offering, setting up a dramatically stronger balance sheet—but also introducing dilution right after the rally. GlobeNewswire Below is a detailed look at what just happened, why WVE stock is suddenly in
9 December 2025
···
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high above $100, on volume far above normal. MarketBeat The catalyst: very strong Phase 1b data for KT‑621, a once‑daily oral STAT6 degrader for atopic dermatitis (eczema) and broader Type 2 inflammatory diseases. GlobeNewswire Below is a full breakdown of today’s news, analyst reactions, and what the move could mean for Kymera stock in the months ahead. Kymera Therapeutics Stock Rockets
8 December 2025
·
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90. That move vaulted Structure into the front rank of the oral obesity drug race and forced investors, analysts and competitors to update their models in real time. Who is Structure Therapeutics and
8 December 2025
···
AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie’s stock is trading just below record highs as investors digest a powerful mix of rising earnings, a fresh dividend increase and a steady drumbeat of positive pipeline news in immunology, neuroscience and oncology. As of the close on Friday, December 5, 2025, AbbVie (NYSE: ABBV) finished at $226.08, down about 1.15% on the day and roughly 7–8% below its 52‑week high of $244.81 set on October 1.MarketWatch+1 That still leaves the company with a market capitalization around $400 billion, firmly placing it among the largest healthcare stocks globally.The Motley Fool+1 Below is a deep dive into the latest news,
7 December 2025
··
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer Inc. (NYSE: PFE) is ending 2025 in better shape than it started, but investors are still debating whether the stock is a high‑yield value opportunity or a classic “value trap.” As of Friday, December 5, 2025, Pfizer shares closed at $26.03, up 1.28% on the day and marking a third straight session of gains. The stock sits about 6% below its 52‑week high of $27.69 (hit on October 3) and roughly 24% above its April low of $20.92.MarketWatch+1 At the same time, Pfizer offers an unusually rich dividend yield of about 6.6%, a fortress‑like balance sheet for a big
6 December 2025
···
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and a positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for its lead essential tremor drug. StockAnalysis+3TradingView+3Stock Titan+3 By late morning U.S. trading, PRAX was changing hands around $265–266, up roughly 40% on the day, with a market capitalization just over $1.1 billion, after hitting a new 52‑week high earlier in the session near $241. Investing.com+1 The stock
5 December 2025
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

As of the close on December 4, 2025, Merck & Co., Inc. (NYSE: MRK) shares finished at $100.86, down about 1.4% on the day, with after‑hours trading essentially flat around $100.83. The stock sits near the upper end of its 52‑week range of $73.31–$105.84, with a market value of roughly $250 billion, a trailing P/E around 13.3 and a forward P/E just under 12.MarketBeat+3StockAnalysis+3StockAnalysis+3 That defensive valuation, combined with a freshly raised dividend and a packed news pipeline, is keeping MRK firmly on the radar of income investors and growth‑oriented healthcare buyers alike. Below is a detailed, news‑ready rundown of
4 December 2025
··
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly exceeding 100–130%, according to MarketBeat, Investing.com and other real‑time data providers. 24/7 MarketNews+3MarketBeat+3StockAnalysis+3 At the heart of this move are two catalysts: Together, these updates have ignited speculative interest in a company that, until recently, was fighting to stay listed
4 December 2025
··
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints.GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about CAPR stock heading into this inflection point. Key Takeaways Capricor Stock Today: A Biotech Super‑Spike As of early afternoon on December 3, 2025, Capricor Therapeutics (NASDAQ: CAPR) was trading around $39–40 per share, up from approximately $6.36 at the previous close.
3 December 2025
···
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH 2025 is impressive, and investors are reassessing the stock’s value, dividend and medium‑term growth story. Below is a deep dive into today’s key news, current price, latest forecasts and what it all might mean for BMY stock. This article is for information only and is not investment advice. BMY Stock Snapshot on 1 December 2025 In other words: BMY is
2 December 2025
·
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic pipeline. This article pulls together the most relevant current Pfizer stock news as of November 30, 2025, and explains what it may mean for PFE shareholders. Key Takeaways Pfizer Stock Today: Price, Performance and Valuation Pfizer’s shares last closed at about $25.74 on November 28, 2025, according to exchange data and several market data providers. StockAnalysis Over the past 12
30 November 2025
····
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As of the close on Friday, November 28, Merck shares finished at $104.83, just off a record intraday high of $105.84 set earlier in the week.StockAnalysis+1 The stock is up roughly 21% over the past month and about 7–8% year‑to‑date, according to recent performance data and independent valuation analysis.Simply Wall St+2FinanceCharts+2 Today’s update pulls together the most important Merck stock news
29 November 2025
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly and Company (NYSE: LLY) is catching its breath after one of the wildest runs any pharmaceutical stock has ever seen. On November 29, 2025, the share price is easing off record highs, but the company is still hovering near the rarefied air of a trillion‑dollar valuation and sitting on massive gains for the year. Smartkarma+1 This piece walks through what’s happening with Eli Lilly’s stock today, why it ran so hard in November, how new U.S. drug‑pricing deals and obesity drugs feed into the story, and what risks are starting to flash on the dashboard. Eli Lilly Stock
29 November 2025
··
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

On Friday, 28 November 2025, Merck & Co., Inc. (NYSE: MRK) continued to trade near its 52‑week highs as a wave of fresh institutional filings, bullish research notes, and recent oncology approvals kept the spotlight firmly on the pharmaceutical giant. The stock closed around $104.5 per share, after trading between roughly $104 and $105 on the day, leaving Merck’s market capitalization near $260 billion.Yahoo Finance+1 While the share price is up only about 2–3% over the past year, nearly all of that gain has arrived in the last month: one recent analysis notes a 20.8% jump over the past 30
28 November 2025
···
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie Inc. (NYSE: ABBV) is trading lower today, but the big pharma giant remains near multi-year highs as investors digest a powerful mix of good news (a major FDA approval, strong Q3 numbers) and growing policy headwinds from U.S. Medicare drug price cuts. Below is a full wrap-up of what’s happening with AbbVie stock today, November 26, 2025, and the key headlines driving sentiment. AbbVie (ABBV) stock price today: mild pullback after strong run As of early afternoon U.S. trading on Wednesday, AbbVie stock is changing hands around $227.41, down about 1.9% on the day. The shares opened at $232.04,
26 November 2025
··
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and a low around $25.24. That puts PFE stock in the middle of its 52‑week range between $20.92 and $27.69, with a market capitalization of roughly $143 billion.Stock Invest+1 Behind the modest move higher lies a busy news backdrop: Below is a detailed look at Pfizer stock today, the latest catalysts, and what they could mean for PFE’s outlook. Pfizer (PFE)
25 November 2025
···
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8 and $5.2 per share. INDmoney On Monday, November 24, ALT: According to short‑term technical data, ALT has risen in 6 of the last 10 trading days and is up almost 20% over the past two weeks, as traders reposition ahead
25 November 2025
··
Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Date: November 25, 2025 Johnson & Johnson (NYSE: JNJ) heads into Tuesday’s session at or near record highs, riding a wave of bullish options activity, a key ex‑dividend date today and a string of growth-focused pipeline moves in cancer and neuroscience. As of the latest completed trading session on Monday, November 24, JNJ was trading around $206 per share, close to its 12‑month high just under $207, with a 12‑month low near $141, a price/earnings ratio around 20 and a dividend yield in the ballpark of 2.5%–2.6%.MarketBeat+1 The stock is up more than 7% since the first trading day of
25 November 2025
··
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly’s stock is entering the new week as one of the most closely watched names on Wall Street. As of this weekend (Sunday, November 23, 2025), LLY is trading near $1,060 per share, valuing the company at roughly $1 trillion, after becoming the first drugmaker ever to join the trillion‑dollar market‑cap club. Reuters At the same time, new headlines today highlight rising institutional ownership, aggressive analyst upgrades, and an emerging GLP‑1 price war that could reshape the economics of the obesity drug market Eli Lilly currently dominates. 1. LLY stock snapshot after the $1 trillion milestone On November 21,
23 November 2025
··
1 … 4 5 6 7 8

Stock Market Today

KLA stock price jumps 8% as chip rebound lifts KLAC — what to know before Monday

KLA stock price jumps 8% as chip rebound lifts KLAC — what to know before Monday

8 February 2026
KLA Corp shares surged 8.4% to $1,442.95 Friday, leading gains in chip-equipment stocks after Amazon announced a major increase in capital spending. About 1.6 million KLA shares traded as the PHLX semiconductor index rose 5.7%. KLA’s board declared a $1.90 quarterly dividend, payable March 3 to holders as of Feb. 17. Applied Materials and Lam Research also rallied sharply into the close.
CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

8 February 2026
Commonwealth Bank of Australia closed Friday down 0.23% at A$158.91, outperforming a 2.03% drop in the S&P/ASX 200. Investors await CBA’s half-year results on Feb. 11 and commentary from CEO Matt Comyn. The Reserve Bank’s recent cash-rate hike to 3.85% and upcoming mortgage repricing are in focus. CBA flagged A$68 million in provisions and A$53 million in non-recurring income items.
Go toTop